{
  "meta": {
    "id": "test29",
    "title": "Mid Day Module (Medicine-10) - 2024-12-22",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "A 40-year-old male presents with a family history of early-onset emphysema. Pulmonary function tests reveal airflow obstruction that does not improve significantly with bronchodilators. What is the most appropriate initial diagnostic test?",
      "options": [
        {
          "label": "A",
          "text": "Alpha-1 antitrypsin (AAT) level measurement",
          "correct": true
        },
        {
          "label": "B",
          "text": "Chest X-ray",
          "correct": false
        },
        {
          "label": "C",
          "text": "High-resolution computed tomography (HRCT) scan of the chest",
          "correct": false
        },
        {
          "label": "D",
          "text": "Genetic testing for cystic fibrosis",
          "correct": false
        }
      ],
      "correct_answer": "A. Alpha-1 antitrypsin (AAT) level measurement",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Chest X-ray : While chest X-ray may reveal findings suggestive of emphysema, it is not specific for AAT deficiency and may not establish a definitive diagnosis.</li><li>\u2022 Option B. Chest X-ray</li><li>\u2022 Option C. High-resolution computed tomography (HRCT) scan of the chest : HRCT may show characteristic changes of emphysema, but it is not specific for AAT deficiency and may not be necessary as an initial diagnostic test.</li><li>\u2022 Option C. High-resolution computed tomography (HRCT) scan of the chest</li><li>\u2022 Option D. Genetic testing for cystic fibrosis : Genetic testing for cystic fibrosis is not indicated in the absence of clinical features suggestive of the condition, such as pancreatic insufficiency and elevated sweat chloride levels.</li><li>\u2022 Option D. Genetic testing for cystic fibrosis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Alpha-1 antitrypsin (AAT) level measurement is the initial diagnostic test for suspected AAT deficiency helps in establishing a timely and accurate diagnosis to guide management decisions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b1d355be",
      "audio": ""
    },
    {
      "text": "A 45-year-old male presents with fatigue, weakness, and joint pain. Physical examination reveals skin pigmentation as in the image below and hepatomegaly. Laboratory tests show elevated serum ferritin levels and increased transferrin saturation. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Wilson Disease",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hemochromatosis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Alpha1 antitrypsin (A1AT) deficiency",
          "correct": false
        },
        {
          "label": "D",
          "text": "Systemic lupus erythematosus (SLE)",
          "correct": false
        }
      ],
      "correct_answer": "B. Hemochromatosis",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-180615.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Wilson Disease involves copper accumulation and typically presents with liver dysfunction and neuropsychiatric symptoms, not primarily iron overload symptoms.</li><li>\u2022 Option A.</li><li>\u2022 Option C. Alpha1 antitrypsin (A1AT) deficiency is a genetic disorder that can lead to liver disease and lung disease, but it is not associated with iron overload or the specific constellation of symptoms described.</li><li>\u2022 Option C.</li><li>\u2022 Option D. Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect multiple organ systems and cause a wide range of symptoms, but it does not cause iron overload or the specific features described here.</li><li>\u2022 Option D.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 The clinical features of hemochromatosis, includes fatigue, bronze skin pigmentation, hepatomegaly, and elevated serum ferritin levels.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "93fa92fb",
      "audio": ""
    },
    {
      "text": "Which of the following parameters is NOT included in the Child-Turcotte-Pugh (CTP) score to assess the severity of liver disease?",
      "options": [
        {
          "label": "A",
          "text": "Serum albumin level",
          "correct": false
        },
        {
          "label": "B",
          "text": "International normalized ratio (INR)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Serum sodium level",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ascites",
          "correct": false
        }
      ],
      "correct_answer": "C. Serum sodium level",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Serum sodium level</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Serum albumin level: Is included in the CTP score as a measure of the liver's synthetic function.</li><li>\u2022 Option A. Serum albumin level:</li><li>\u2022 Option B. International normalized ratio: INR is included to assess the liver's ability to synthesize clotting factors.</li><li>\u2022 Option B. International normalized ratio:</li><li>\u2022 Option D. Ascites: The presence and severity of ascites are used to evaluate the liver's synthetic function and portal hypertension.</li><li>\u2022 Option D. Ascites:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 To recognize the components of the Child-Turcotte-Pugh score and understand that serum sodium level is not included in this assessment of liver disease severity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a9874f38",
      "audio": ""
    },
    {
      "text": "A 45-year-old female with no significant medical history presents with abdominal swelling and discomfort. A diagnostic paracentesis shows a SAAG of 0.9 g/dL. Which of the following conditions is most likely associated with her ascites?",
      "options": [
        {
          "label": "A",
          "text": "Budd-Chiari syndrome",
          "correct": false
        },
        {
          "label": "B",
          "text": "Congestive heart failure",
          "correct": false
        },
        {
          "label": "C",
          "text": "Malignant ascites",
          "correct": true
        },
        {
          "label": "D",
          "text": "Hepatic venous outflow obstruction",
          "correct": false
        }
      ],
      "correct_answer": "C. Malignant ascites",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Options A. Budd-Chiari syndrome and D. Hepatic venous outflow obstruction : Both typically lead to portal hypertension and would more likely present with a SAAG greater than 1.1 g/dL.</li><li>\u2022 Options A. Budd-Chiari syndrome and D. Hepatic venous outflow obstruction</li><li>\u2022 Option B. Congestive heart failure: Can cause ascites due to increased hydrostatic pressure in the systemic and portal venous systems, typically resulting in a SAAG greater than 1.1 g/dL, indicating that the ascites is due to portal hypertension secondary to heart failure.</li><li>\u2022 Option B. Congestive heart failure:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 A SAAG lower than 1.1 g/dL suggests the ascites is not due to portal hypertension and that malignant ascites is caused by the direct spread of cancer in the peritoneal cavity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "22dfc38a",
      "audio": ""
    },
    {
      "text": "A 55-year-old man with a history of cirrhosis due to chronic hepatitis C infection presents with new-onset ascites. What is the most appropriate initial step in the management of his ascites?",
      "options": [
        {
          "label": "A",
          "text": "Increase the dose of his current diuretic",
          "correct": false
        },
        {
          "label": "B",
          "text": "Start antibiotic prophylaxis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Perform a large-volume paracentesis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Restrict dietary sodium",
          "correct": true
        }
      ],
      "correct_answer": "D. Restrict dietary sodium",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Restrict dietary sodium</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Increase the dose of his current diuretic: Increasing the dose of his current diuretic without first attempting dietary modifications may lead to electrolyte imbalances and kidney injury.</li><li>\u2022 Option A. Increase the dose of his current diuretic:</li><li>\u2022 Option B. Start antibiotic prophylaxis: Antibiotic prophylaxis is indicated in specific situations, such as prior episodes of spontaneous bacterial peritonitis (SBP), but not as an initial step for all cases of ascites.</li><li>\u2022 Option B. Start antibiotic prophylaxis:</li><li>\u2022 Option C. Perform a large-volume paracentesis: Large-volume paracentesis is typically reserved for tense ascites causing respiratory discomfort or as a diagnostic procedure.</li><li>\u2022 Option C. Perform a large-volume paracentesis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Dietary sodium restriction is the initial management strategy for patients with cirrhosis presenting with ascites.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "697b4074",
      "audio": ""
    },
    {
      "text": "Child-Pugh score of 8 comes under ?",
      "options": [
        {
          "label": "A",
          "text": "Child-Pugh class A",
          "correct": false
        },
        {
          "label": "B",
          "text": "Child-Pugh class B",
          "correct": true
        },
        {
          "label": "C",
          "text": "Child-Pugh class C",
          "correct": false
        },
        {
          "label": "D",
          "text": "Child-Pugh class D",
          "correct": false
        }
      ],
      "correct_answer": "B. Child-Pugh class B",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Child-Pugh class B</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "74b0fe28",
      "audio": ""
    },
    {
      "text": "A 72-year-old woman with a history of chronic obstructive pulmonary disease (COPD) presents to the clinic with increased shortness of breath, wheezing, and productive cough for the past 2 days. She uses a short-acting bronchodilator as needed. Which of the following is the most appropriate initial treatment?",
      "options": [
        {
          "label": "A",
          "text": "Start systemic corticosteroids",
          "correct": true
        },
        {
          "label": "B",
          "text": "Prescribe a long-acting muscarinic antagonist",
          "correct": false
        },
        {
          "label": "C",
          "text": "Initiate antibiotic therapy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Increase the dose of the short-acting bronchodilator",
          "correct": false
        }
      ],
      "correct_answer": "A. Start systemic corticosteroids",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Prescribing a long-acting muscarinic antagonist: Prescribing a long-acting muscarinic antagonist (LAMA) is a good option for long-term management of COPD to improve symptoms and reduce exacerbations, but it is not the first choice for treating an acute exacerbation.</li><li>\u2022 Option B. Prescribing a long-acting muscarinic antagonist:</li><li>\u2022 Option C. Initiate antibiotic therapy: Antibiotic therapy may be indicated if there is a strong suspicion or evidence of a bacterial infection contributing to the exacerbation, such as increased sputum purulence, but it is not the standard initial treatment for all acute COPD exacerbations.</li><li>\u2022 Option C. Initiate antibiotic therapy:</li><li>\u2022 Option D. Increase the dose of the short-acting bronchodilator: Increasing the dose of a short-acting bronchodilator can provide symptomatic relief and is often part of the management of acute exacerbations, but it may not be sufficient on its own without addressing the inflammation with corticosteroids.</li><li>\u2022 Option D. Increase the dose of the short-acting bronchodilator:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Systemic corticosteroids are an appropriate initial treatment for an acute exacerbation of COPD, as they address the underlying airway inflammation and can improve symptoms and lung function.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a0cb2867",
      "audio": ""
    },
    {
      "text": "A 62-year-old man with a history of cirrhosis due to chronic hepatitis B infection presents with altered mental status. On examination, he exhibits asterixis. Which of the following best describes this patient's condition?",
      "options": [
        {
          "label": "A",
          "text": "Acute stroke",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hepatic encephalopathy",
          "correct": true
        },
        {
          "label": "C",
          "text": "Alzheimer's disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "Normal pressure hydrocephalus",
          "correct": false
        }
      ],
      "correct_answer": "B. Hepatic encephalopathy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Hepatic encephalopathy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Acute stroke: Typically presents with sudden onset neurological deficits such as weakness or numbness on one side of the body, difficulty speaking, or facial drooping, which are not described in this case.</li><li>\u2022 Option A. Acute stroke:</li><li>\u2022 Option C. Alzheimer's disease: Is a progressive neurodegenerative disorder characterized by gradual memory loss, cognitive decline, and changes in behavior, but it does not typically present with acute changes or asterixis.</li><li>\u2022 Option C. Alzheimer's disease:</li><li>\u2022 Option D. Normal pressure hydrocephalus: Is characterized by the triad of gait disturbance, urinary incontinence, and cognitive decline, but the acute onset and presence of asterixis are more indicative of hepatic encephalopathy in the context of known liver disease.</li><li>\u2022 Option D. Normal pressure hydrocephalus:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hepatic encephalopathy's characteristic presentation in a patient with underlying liver disease, includes altered mental status, confusion, difficulty with tasks, and asterixis, which highlights liver function in neuropsychiatric status.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "90e80287",
      "audio": ""
    },
    {
      "text": "Which of the following is the most appropriate long-term treatment to prevent further episodes of hepatic encephalopathy in a patient with advanced cirrhosis?",
      "options": [
        {
          "label": "A",
          "text": "Oral lactulose",
          "correct": true
        },
        {
          "label": "B",
          "text": "Intravenous albumin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Oral propranolol",
          "correct": false
        },
        {
          "label": "D",
          "text": "High-dose vitamin K",
          "correct": false
        }
      ],
      "correct_answer": "A. Oral lactulose",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Oral lactulose</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Intravenous albumin: Intravenous albumin is used in the management of patients with cirrhosis and complications such as spontaneous bacterial peritonitis or hepatorenal syndrome, but it is not a standard treatment for preventing hepatic encephalopathy.</li><li>\u2022 Option B. Intravenous albumin:</li><li>\u2022 Option C. Oral propranolol: Oral propranolol is used for primary prophylaxis of variceal bleeding in cirrhotic patients by reducing portal hypertension, not for preventing hepatic encephalopathy.</li><li>\u2022 Option C. Oral propranolol:</li><li>\u2022 Option D. High-dose vitamin K: High-dose vitamin K is sometimes used in cirrhotic patients to correct coagulopathy, but it does not play a role in the prevention of hepatic encephalopathy.</li><li>\u2022 Option D. High-dose vitamin K:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Oral lactulose is the most appropriate long-term treatment for preventing recurrent episodes of hepatic encephalopathy in patients with advanced cirrhosis, due to its mechanism of reducing blood ammonia levels.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d71bae88",
      "audio": ""
    },
    {
      "text": "A 62-year-old woman with a history of non-alcoholic steatohepatitis (NASH) presents with worsening fatigue and abdominal distension. An abdominal ultrasound reveals a nodular liver and ascites. Which additional finding would most suggest the presence of hepatocellular carcinoma (HCC)?",
      "options": [
        {
          "label": "A",
          "text": "Hypoglycemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Elevated alpha-fetoprotein (AFP)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Hyponatremia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypoalbuminemia",
          "correct": false
        }
      ],
      "correct_answer": "B. Elevated alpha-fetoprotein (AFP)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Elevated alpha-fetoprotein (AFP)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hypoglycemia: Hypoglycemia can occur in advanced liver disease due to the liver's impaired gluconeogenesis, but it is not specific for HCC.</li><li>\u2022 Option A. Hypoglycemia:</li><li>\u2022 Option C. Hyponatremia: Hyponatremia is common in advanced liver disease, particularly with the development of ascites and portal hypertension, but it is not specific for HCC.</li><li>\u2022 Option C. Hyponatremia:</li><li>\u2022 Option D. Hypoalbuminemia: Hypoalbuminemia is indicative of liver dysfunction and is a common feature of cirrhosis and advanced liver disease but does not specifically suggest HCC.</li><li>\u2022 Option D. Hypoalbuminemia:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 An elevated alpha-fetoprotein (AFP) level, particularly in a patient with risk factors and liver disease such as NASH, is suggestive of hepatocellular carcinoma (HCC).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "190b8e39",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents with a family history of breast and ovarian cancer. Genetic testing reveals a germline mutation in a gene that normally functions to inhibit cell cycle progression and repair DNA damage. Which of the following best describes the role of the affected gene in this patient's cancer predisposition?",
      "options": [
        {
          "label": "A",
          "text": "It promotes cell growth and division",
          "correct": false
        },
        {
          "label": "B",
          "text": "It controls proto-oncogene activity",
          "correct": true
        },
        {
          "label": "C",
          "text": "It induces angiogenesis",
          "correct": false
        },
        {
          "label": "D",
          "text": "It evades apoptosis",
          "correct": false
        }
      ],
      "correct_answer": "B. It controls proto-oncogene activity",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Promote cell growth and division: This is the opposite of what tumor suppressor genes do. They actually inhibit cell growth and division, acting as a brake on the cell cycle.</li><li>\u2022 Option A. Promote cell growth and division:</li><li>\u2022 Option C. Induce angiogenesis: Angiogenesis (the formation of new blood vessels) is often promoted by cancer cells, not suppressed. Tumor suppressor genes may indirectly inhibit angiogenesis by preventing uncontrolled cell growth.</li><li>\u2022 Option C. Induce angiogenesis:</li><li>\u2022 Option D. Evade apoptosis: Apoptosis (programmed cell death) is a crucial process for eliminating damaged or abnormal cells. Tumor suppressor genes often promote apoptosis, not evade it.</li><li>\u2022 Option D. Evade apoptosis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 The primary function of tumor suppressor genes is to control proto-oncogene activity, thereby preventing uncontrolled cell growth and maintaining genomic stability. Inherited mutations in tumor suppressor genes can significantly increase an individual's risk of developing certain types of cancer.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3a12a4c7",
      "audio": ""
    },
    {
      "text": "A 56-year-old man presents to his primary care physician with a 3-month history of worsening fatigue and unintentional weight loss. His past medical history is significant for hypertension and type 2 diabetes, both well-controlled with medications. He has a 30-pack-year smoking history but quit 10 years ago. Physical examination reveals pallor and generalized lymphadenopathy. Laboratory studies show anemia and thrombocytopenia. A peripheral blood smear demonstrates blast cells. A bone marrow biopsy is performed, and the pathology report indicates acute myeloid leukemia (AML) with a specific chromosomal translocation. Further molecular studies reveal a mutation leading to increased activity of histone deacetylases (HDACs), which is known to be associated with a poor prognosis in this type of leukemia. The oncologist discusses treatment options with the patient, focusing on the potential use of HDAC inhibitors as part of his chemotherapy regimen. Which of the following is not a HDAC inhibitor?",
      "options": [
        {
          "label": "A",
          "text": "Ivosidenib",
          "correct": true
        },
        {
          "label": "B",
          "text": "Romidepsin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Panobinostat",
          "correct": false
        },
        {
          "label": "D",
          "text": "Belinostat",
          "correct": false
        }
      ],
      "correct_answer": "A. Ivosidenib",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B) Romidepsin, C)  panobinostat, and D) belinostat are all examples of HDAC inhibitors. These drugs work by inhibiting histone deacetylases, which are enzymes involved in the epigenetic regulation of gene expression. By inhibiting these enzymes, HDAC inhibitors can induce cell cycle arrest, differentiation, and apoptosis of cancer cells, making them useful in the treatment of certain hematologic malignancies and solid tumors.</li><li>\u2022 Option B) Romidepsin, C)  panobinostat, and D) belinostat</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 HDAC inhibitors, such as romidepsin, panobinostat, and belinostat, are used in cancer therapy to inhibit histone deacetylases, leading to epigenetic modulation of gene expression and inducing apoptosis in cancer cells. Ivosidenib, on the other hand, is an IDH1 inhibitor used in the treatment of cancers with IDH1 mutations.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a87f8093",
      "audio": ""
    },
    {
      "text": "In the context of cancer development, which of the following statements best differentiates proto-oncogenes from tumor suppressor genes?",
      "options": [
        {
          "label": "A",
          "text": "Proto-oncogenes causes cancer by gain of function mutations, while tumor suppressor genes cause cancer due to loss of function mutations.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Proto-oncogenes are typically inactivated in cancer, while tumor suppressor genes are overactivated.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Proto-oncogenes are exclusively found in malignant tumors, while tumor suppressor genes are found in benign tumors.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Proto-oncogenes encode for growth factors, while tumor suppressor genes encode for growth factor receptors.",
          "correct": false
        }
      ],
      "correct_answer": "A. Proto-oncogenes causes cancer by gain of function mutations, while tumor suppressor genes cause cancer due to loss of function mutations.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B . Proto-oncogenes are not typically inactivated in cancer; they are activated or overexpressed. Tumor suppressor genes are often inactivated or under expressed in cancer.</li><li>\u2022 Option B</li><li>\u2022 Option C. Both proto-oncogenes and tumor suppressor genes can be involved in both malignant and benign tumors.</li><li>\u2022 Option C.</li><li>\u2022 Option D. Proto-oncogenes and tumor suppressor genes can encode a variety of proteins, not limited to growth factors and growth factor receptors.</li><li>\u2022 Option D.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Proto-oncogenes and tumor suppressor genes are two key classes of genes involved in cancer development. Proto-oncogenes promote cell growth and proliferation and can lead to cancer when mutated to gain function. Tumor suppressor genes normally inhibit cell growth, and their inactivation or loss of function can contribute to cancer development.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b564424a",
      "audio": ""
    },
    {
      "text": "Which of the following is an example of an epigenetic change that can contribute to cancer development?",
      "options": [
        {
          "label": "A",
          "text": "Point mutation in the p53 gene",
          "correct": false
        },
        {
          "label": "B",
          "text": "Deletion of the RB1 gene",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hypermethylation of the promoter region of a tumor suppressor gene",
          "correct": true
        },
        {
          "label": "D",
          "text": "Translocation between chromosomes 9 and 22",
          "correct": false
        }
      ],
      "correct_answer": "C. Hypermethylation of the promoter region of a tumor suppressor gene",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A. Point mutation in the p53 gene: This is a genetic alteration where a single nucleotide in the DNA sequence of the p53 gene is changed. This can lead to the production of a dysfunctional p53 protein, which is a tumor suppressor.</li><li>\u2022 Option A. Point mutation in the p53 gene:</li><li>\u2022 Option B. Deletion of the RB1 gene: This is also a genetic alteration where a portion of the RB1 gene, another tumor suppressor, is removed. The absence of the RB1 protein can contribute to uncontrolled cell growth.</li><li>\u2022 Option B. Deletion of the RB1 gene:</li><li>\u2022 Option D. Translocation between chromosomes 9 and 22: This is a chromosomal rearrangement where a piece of chromosome 9 is transferred to chromosome 22, and vice versa. This translocation creates a new fusion gene, often the BCR-ABL gene, which drives the development of chronic myeloid leukemia (CML).</li><li>\u2022 Option D. Translocation between chromosomes 9 and 22:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Epigenetic modifications, like DNA methylation, play a significant role in carcinogenesis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f683fbf2",
      "audio": ""
    },
    {
      "text": "Which of the following HPV genes is MOST directly implicated in the development of cervical cancer?",
      "options": [
        {
          "label": "A",
          "text": "E2",
          "correct": false
        },
        {
          "label": "B",
          "text": "E4",
          "correct": false
        },
        {
          "label": "C",
          "text": "E6",
          "correct": true
        },
        {
          "label": "D",
          "text": "E8",
          "correct": false
        }
      ],
      "correct_answer": "C. E6",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. E2: E2 is involved in viral replication and gene expression regulation. While important for the HPV lifecycle, it's not directly implicated in cellular transformation and cancer development.</li><li>\u2022 Option A. E2:</li><li>\u2022 Option B. E4: E4 plays a role in viral release and assembly. It's not considered a major oncogenic protein in the context of cervical cancer.</li><li>\u2022 Option B. E4:</li><li>\u2022 Option D. E8: There is no E8 gene in the HPV genome.</li><li>\u2022 Option D. E8:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The E6 and E7 proteins are the primary oncoproteins of HPV that drive the development of cervical cancer by interfering with critical cellular pathways that regulate cell growth and survival.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bca5a36b",
      "audio": ""
    },
    {
      "text": "A patient presents with mantle cell lymphoma (MCL). Which of the following genetic alterations is MOST likely associated with this malignancy?",
      "options": [
        {
          "label": "A",
          "text": "CDKN2A (p16INK4A) mutation",
          "correct": false
        },
        {
          "label": "B",
          "text": "CDKN1B (p27) mutation",
          "correct": false
        },
        {
          "label": "C",
          "text": "CCND1 amplification",
          "correct": true
        },
        {
          "label": "D",
          "text": "TP53 mutation",
          "correct": false
        }
      ],
      "correct_answer": "C. CCND1 amplification",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. CDKN2A (p16INK4A) mutation: While CDKN2A mutations can be seen in various cancers, they are more commonly associated with melanoma and other solid tumors. In mantle cell lymphoma, CDKN2A deletions are associated with poor prognosis but are not the primary driver of the disease.</li><li>\u2022 Option A. CDKN2A (p16INK4A) mutation:</li><li>\u2022 Option B. CDKN1B (p27) mutation: Mutations in CDKN1B are associated with MEN4 syndrome (multiple endocrine neoplasia type 4) and can be seen in other cancers, but not typically in mantle cell lymphoma.</li><li>\u2022 Option B. CDKN1B (p27) mutation:</li><li>\u2022 Option D. TP53 mutation: TP53 is a tumor suppressor gene, and mutations are found in various cancers. While TP53 mutations can occur in MCL and are associated with a worse prognosis, they are not the primary genetic alteration driving the disease.</li><li>\u2022 Option D. TP53 mutation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 CCND1 amplification is a hallmark of mantle cell lymphoma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "133f64d1",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman is diagnosed with breast cancer and is referred to an oncologist for treatment. The tumor is found to be estrogen receptor-positive and HER2-negative. The oncologist discusses the use of a targeted therapy that specifically interferes with the cell cycle of cancer cells, thereby inhibiting their proliferation. The medication targets a specific phase of the cell cycle, leading to cell cycle arrest and eventual apoptosis of the cancer cells. Which of the following best describes the mechanism of action of the medication likely prescribed to this patient?",
      "options": [
        {
          "label": "A",
          "text": "Inhibition of cyclin-dependent kinases (CDKs) in the G1/S phase transition",
          "correct": true
        },
        {
          "label": "B",
          "text": "Activation of topoisomerase II in the S phase",
          "correct": false
        },
        {
          "label": "C",
          "text": "Inhibition of microtubule formation in the M phase",
          "correct": false
        },
        {
          "label": "D",
          "text": "Activation of DNA repair enzymes in the G2 phase",
          "correct": false
        }
      ],
      "correct_answer": "A. Inhibition of cyclin-dependent kinases (CDKs) in the G1/S phase transition",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Activation of topoisomerase II in the S phase : Topoisomerase II inhibitors, such as etoposide, work by interfering with the action of topoisomerase II, an enzyme involved in DNA replication and cell division during the S phase. This mechanism is not specific to CDK inhibitors used in breast cancer treatment.</li><li>\u2022 Option B. Activation of topoisomerase II in the S phase</li><li>\u2022 Option C. Inhibition of microtubule formation in the M phase : Microtubule inhibitors, such as taxanes (e.g., paclitaxel), target the M phase of the cell cycle by preventing the formation of microtubules, which are essential for chromosome separation during cell division. This mechanism is different from that of CDK inhibitors.</li><li>\u2022 Option C. Inhibition of microtubule formation in the M phase</li><li>\u2022 Option D. Activation of DNA repair enzymes in the G2 phase : This option is not a common mechanism for targeted therapy in breast cancer. Drugs that target DNA repair pathways typically work by inhibiting, not activating, DNA repair enzymes to prevent cancer cells from repairing DNA damage.</li><li>\u2022 Option D. Activation of DNA repair enzymes in the G2 phase</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Cyclin-dependent kinase (CDK) inhibitors, such as palbociclib, ribociclib, and abemaciclib, are used in the treatment of estrogen receptor-positive, HER2-negative breast cancer. They work by inhibiting CDK4/6, leading to cell cycle arrest at the G1/S transition and preventing cancer cell proliferation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4065a86c",
      "audio": ""
    },
    {
      "text": "A 28-year-old woman presents with a family history of early-onset colon cancer and multiple family members affected by various types of cancer. Which of the following genetic mutations is MOST likely responsible for her increased cancer risk?",
      "options": [
        {
          "label": "A",
          "text": "BRCA1 mutation",
          "correct": false
        },
        {
          "label": "B",
          "text": "MUTYH mutation",
          "correct": false
        },
        {
          "label": "C",
          "text": "MSH2 mutation",
          "correct": true
        },
        {
          "label": "D",
          "text": "ATM mutation",
          "correct": false
        }
      ],
      "correct_answer": "C. MSH2 mutation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. BRCA1 mutation: BRCA1 mutations are primarily associated with increased risks of breast and ovarian cancers. While they can increase the risk of other cancers, the patient's family history of colon cancer makes this less likely.</li><li>\u2022 Option A. BRCA1 mutation:</li><li>\u2022 Option B. MUTYH mutation: MUTYH mutations are associated with MUTYH-associated polyposis (MAP), a hereditary condition that increases the risk of colorectal cancer. However, MAP usually presents with multiple polyps, and the patient's family history doesn't necessarily fit this pattern.</li><li>\u2022 Option B. MUTYH mutation:</li><li>\u2022 Option D. ATM mutation: ATM mutations are associated with ataxia-telangiectasia, a rare neurodegenerative disorder characterized by ataxia, telangiectasias (small dilated blood vessels), and immune deficiencies. While individuals with ataxia-telangiectasia have an increased risk of certain cancers, the presentation in this question doesn't match the typical features of this condition.</li><li>\u2022 Option D. ATM mutation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 MSH2 mutations are associated with Lynch syndrome, a hereditary cancer syndrome that significantly increases the risk of various cancers, including colorectal, endometrial, and ovarian cancer.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ff976101",
      "audio": ""
    },
    {
      "text": "A 38-year-old woman presents to your clinic with a newly discovered breast mass. Her family history is significant for multiple cases of breast and ovarian cancer, including her mother and sister. Genetic testing reveals a germline BRCA1 mutation. Which of the following DNA repair pathways is MOST likely deficient in this patient, contributing to her increased cancer risk?",
      "options": [
        {
          "label": "A",
          "text": "Non-homologous end joining (NHEJ)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Base excision repair (BER)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Homologous recombination (HR)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Single-strand break repair",
          "correct": false
        }
      ],
      "correct_answer": "C. Homologous recombination (HR)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Non-homologous end joining (NHEJ): While important for DNA repair, NHEJ is not the primary pathway affected by BRCA1 mutations.</li><li>\u2022 Option A. Non-homologous end joining (NHEJ):</li><li>\u2022 Option B. Base excision repair (BER): BER is primarily responsible for repairing single-base DNA damage and is not directly affected by BRCA1 mutations.</li><li>\u2022 Option B. Base excision repair (BER):</li><li>\u2022 Option D. Single-strand break repair: This is a broader term encompassing several pathways, including BER and PARP. While PARP inhibitors are used in BRCA-mutant cancers, the primary defect lies in HR.</li><li>\u2022 Option D. Single-strand break repair:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 BRCA1 mutations lead to a deficiency in homologous recombination (HR), a critical DNA repair mechanism. This defect contributes to genomic instability and significantly increases the risk of breast and ovarian cancers in affected individuals.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5556e8d8",
      "audio": ""
    },
    {
      "text": "A 5-year-old child is brought to your clinic by their parents, who are concerned about their child's extreme sensitivity to sunlight. The child easily sunburns and has developed multiple freckles and skin lesions after minimal sun exposure. On examination, you notice dry skin and patches of hypopigmentation. You suspect an underlying genetic disorder affecting DNA repair mechanisms. Which of the following DNA repair pathways is MOST likely deficient in this child?",
      "options": [
        {
          "label": "A",
          "text": "Base excision repair (BER)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Nucleotide excision repair (NER)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Homologous recombination (HR)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Non-homologous end joining (NHEJ)",
          "correct": false
        }
      ],
      "correct_answer": "B. Nucleotide excision repair (NER)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Base excision repair (BER): BER primarily repairs damage to single bases in DNA, often caused by oxidation or alkylation. While important, it's not the primary pathway for repairing the type of damage caused by UV radiation.</li><li>\u2022 Option A. Base excision repair (BER):</li><li>\u2022 Option C. Homologous recombination (HR): HR is a complex process used to repair double-stranded DNA breaks. While critical for genome stability, it's not the main mechanism for repairing UV-induced DNA damage.</li><li>\u2022 Option C. Homologous recombination (HR):</li><li>\u2022 Option D. Non-homologous end joining (NHEJ): Similar to HR, NHEJ repairs double-stranded breaks but does not play a major role in repairing UV-induced damage.</li><li>\u2022 Option D. Non-homologous end joining (NHEJ):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 The inability to repair UV-induced DNA damage in XP leads to a significantly increased risk of skin cancer at a young age, as well as other complications like ocular problems and neurological abnormalities. Early diagnosis and strict sun protection measures are crucial for managing XP.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6cb3aef0",
      "audio": ""
    },
    {
      "text": "A researcher is investigating a new drug that inhibits the formation of the inflammasome complex. Which of the following types of cell death would be MOST directly affected by this drug?",
      "options": [
        {
          "label": "A",
          "text": "Apoptosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Necroptosis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pyroptosis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Necrosis",
          "correct": false
        }
      ],
      "correct_answer": "C. Pyroptosis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Apoptosis: Apoptosis is a programmed cell death pathway, but it is not directly dependent on the inflammasome. It involves a different set of caspases (caspase-3, -6, -7) and is not typically associated with the same inflammatory response as pyroptosis.</li><li>\u2022 Option A. Apoptosis:</li><li>\u2022 Option B. Necroptosis: Necroptosis is another form of programmed cell death, but it is regulated by the RIPK1-RIPK3-MLKL pathway, not the inflammasome.</li><li>\u2022 Option B. Necroptosis:</li><li>\u2022 Option D. Necrosis: Necrosis is an unregulated form of cell death that is typically caused by injury or trauma. It is not a programmed process and is not mediated by the inflammasome.</li><li>\u2022 Option D. Necrosis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 The inflammasome is a multiprotein complex that plays a central role in pyroptosis. It senses danger signals and activates caspase-1, leading to the production of pro-inflammatory cytokines and ultimately cell death with membrane rupture. By inhibiting the inflammasome, the drug would directly block the pyroptotic pathway.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2c0ab4c1",
      "audio": ""
    },
    {
      "text": "A 35-year-old patient presents with painless hematuria and flank pain. Imaging reveals a renal mass with characteristic features of clear cell renal cell carcinoma (RCC). Which of the following genetic alterations is MOST likely involved in the pathogenesis of this tumor?",
      "options": [
        {
          "label": "A",
          "text": "Mutation in BRCA1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amplification of HER2",
          "correct": false
        },
        {
          "label": "C",
          "text": "Loss of function mutation in VHL",
          "correct": true
        },
        {
          "label": "D",
          "text": "Activation of KRAS",
          "correct": false
        }
      ],
      "correct_answer": "C. Loss of function mutation in VHL",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Mutation in BRCA1: BRCA1 is a tumor suppressor gene primarily associated with breast and ovarian cancers. While it can be involved in other cancers, it's not the primary driver of clear cell renal cell carcinoma (RCC).</li><li>\u2022 Option A. Mutation in BRCA1:</li><li>\u2022 Option B. Amplification of HER2: HER2 amplification is a key feature of certain breast cancers and some other malignancies, but not clear cell RCC.</li><li>\u2022 Option B. Amplification of HER2:</li><li>\u2022 Option D. Activation of KRAS: KRAS is an oncogene involved in various cancers, including some types of lung and colon cancer. It is not the hallmark of clear cell RCC.</li><li>\u2022 Option D. Activation of KRAS:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The VHL gene plays a crucial role in oxygen sensing and regulation of blood vessel growth. When VHL is inactivated, it leads to the stabilization and activation of hypoxia-inducible factor (HIF), which promotes angiogenesis (new blood vessel formation) and tumor growth. This is why VHL loss-of-function mutations are so strongly linked to clear cell RCC.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "675174be",
      "audio": ""
    },
    {
      "text": "A 52-year-old man with metastatic melanoma has progressed on previous therapy. You are considering starting him on an immune checkpoint inhibitor along with nivolumab after which you are planning to keep him on nibolumab. Which of the following immune checkpoint molecules is the DIRECT target for the drug which you have planned to give for this patient along with nivolumab?",
      "options": [
        {
          "label": "A",
          "text": "PD-1",
          "correct": false
        },
        {
          "label": "B",
          "text": "PD-L1",
          "correct": false
        },
        {
          "label": "C",
          "text": "CTLA-4",
          "correct": true
        },
        {
          "label": "D",
          "text": "CD80/86",
          "correct": false
        }
      ],
      "correct_answer": "C. CTLA-4",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. PD-1: PD-1 is another inhibitory checkpoint on T cells, but it's targeted by different drugs like nivolumab and pembrolizumab.</li><li>\u2022 Option A. PD-1:</li><li>\u2022 Option B. PD-L1: PD-L1 is the ligand for PD-1, and it's also targeted by different drugs like atezolizumab and durvalumab.</li><li>\u2022 Option B. PD-L1:</li><li>\u2022 Option D. CD80/86: These are the ligands for CTLA-4, but ipilimumab doesn't directly bind to them; it binds to CTLA-4 itself.</li><li>\u2022 Option D. CD80/86:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Understanding the specific targets of immune checkpoint inhibitors is crucial for selecting the right therapy for different types of cancer and managing potential immune-related side effects.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bce25a5b",
      "audio": ""
    },
    {
      "text": "A researcher is studying the metabolic profile of cancer cells and notices that they primarily produce energy through glycolysis, even in the presence of oxygen. This phenomenon is BEST described as:",
      "options": [
        {
          "label": "A",
          "text": "Oxidative phosphorylation",
          "correct": false
        },
        {
          "label": "B",
          "text": "The Cori cycle",
          "correct": false
        },
        {
          "label": "C",
          "text": "The Warburg effect",
          "correct": true
        },
        {
          "label": "D",
          "text": "Gluconeogenesis",
          "correct": false
        }
      ],
      "correct_answer": "C. The Warburg effect",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Oxidative phosphorylation: This is the normal process of energy production in cells with sufficient oxygen. It occurs in the mitochondria and is much more efficient at generating ATP than glycolysis.</li><li>\u2022 Option A. Oxidative phosphorylation:</li><li>\u2022 Option B. The Cori cycle: This is a metabolic pathway that involves the interconversion of lactate and glucose between the liver and muscles. While lactate is a byproduct of glycolysis, the Cori cycle itself isn't the primary energy production method in cancer cells.</li><li>\u2022 Option B. The Cori cycle:</li><li>\u2022 Option D. Gluconeogenesis: This is the process of synthesizing glucose from non-carbohydrate sources (like amino acids or lactate). While cancer cells may engage in gluconeogenesis, it's not the main energy-producing pathway they rely on.</li><li>\u2022 Option D. Gluconeogenesis:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The Warburg effect is a hallmark of cancer metabolism and has implications for both cancer diagnosis and potential therapeutic targets.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a654e717",
      "audio": ""
    },
    {
      "text": "A 32-year-old male presents with progressive headaches, gait instability, and visual disturbances. MRI was taken and shown below. Patient also has, multiple retinal angiomas. His family history is notable for his father died of uncontrolled hypertension during his 50s and his paternal side uncle was diagnosed with a brain tumor and uncontrolled hypertension along with frequent anger outbursts seeking psychiatric counselling. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Neurofibromatosis type 2",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tuberous sclerosis complex",
          "correct": false
        },
        {
          "label": "C",
          "text": "Von Hippel-Lindau disease",
          "correct": true
        },
        {
          "label": "D",
          "text": "Li-Fraumeni syndrome",
          "correct": false
        }
      ],
      "correct_answer": "C. Von Hippel-Lindau disease",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-172814.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Neurofibromatosis type 2: This condition is associated with bilateral vestibular schwannomas (tumors of the nerve responsible for hearing and balance) and other nerve tumors, not the specific findings in this case.</li><li>\u2022 Option A. Neurofibromatosis type 2:</li><li>\u2022 Option B. Tuberous sclerosis complex: This syndrome is associated with benign tumors in various organs, including the brain, kidneys, heart, eyes, lungs, and skin. The characteristic brain tumors are cortical tubers and subependymal giant cell astrocytomas, not hemangioblastomas.</li><li>\u2022 Option B. Tuberous sclerosis complex:</li><li>\u2022 Option D. Li-Fraumeni syndrome: This syndrome predisposes individuals to a wide range of cancers, including sarcomas, breast cancer, brain tumors, and leukemia. It is not typically associated with the specific combination of findings in this patient.</li><li>\u2022 Option D. Li-Fraumeni syndrome:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The presence of a cerebellar hemangioblastoma and retinal angiomas, especially in conjunction with a suggestive family history, should raise strong suspicion for Von Hippel-Lindau disease. Early diagnosis and surveillance are crucial for managing this condition and preventing complications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "beeb4387",
      "audio": ""
    },
    {
      "text": "A 28-year-old man presents with multiple pigmented skin lesions and cardiac myxomas. He also reports a family history of sudden cardiac death. Which gene is MOST likely to be mutated in this patient?",
      "options": [
        {
          "label": "A",
          "text": "PRKAR1A",
          "correct": true
        },
        {
          "label": "B",
          "text": "CDKN2A",
          "correct": false
        },
        {
          "label": "C",
          "text": "SDH",
          "correct": false
        },
        {
          "label": "D",
          "text": "MET",
          "correct": false
        }
      ],
      "correct_answer": "A. PRKAR1A",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. CDKN2A : This gene is associated with melanoma and pancreatic cancer in the context of familial atypical multiple mole melanoma (FAMMM) syndrome. While pigmented skin lesions can be present in FAMMM, cardiac myxomas and a family history of sudden cardiac death are not characteristic features.</li><li>\u2022 Option B. CDKN2A</li><li>\u2022 Option C. SDH : Mutations in SDH genes are linked to hereditary paraganglioma-pheochromocytoma syndrome, which primarily manifests with tumors of the adrenal glands and nervous system. Cardiac myxomas and pigmented skin lesions are not associated with this syndrome.</li><li>\u2022 Option C. SDH</li><li>\u2022 Option D. MET : MET mutations are involved in hereditary papillary renal cell carcinoma. This condition is not typically associated with cardiac myxomas or pigmented skin lesions.</li><li>\u2022 Option D. MET</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The specific constellation of findings in this patient, including pigmented skin lesions, cardiac myxomas, and a family history of sudden cardiac death, is strongly suggestive of Carney complex, a rare autosomal dominant disorder caused by mutations in the PRKAR1A gene.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "38300b32",
      "audio": ""
    },
    {
      "text": "A 7-year-old boy is brought to the pediatrician due to concerns about his small stature and sun sensitivity. He has also had recurrent respiratory infections. On physical examination, he is noted to have a photosensitive rash on his face, microcephaly, and low body weight for his age. Which of the following DNA repair pathways is MOST likely deficient in this child?",
      "options": [
        {
          "label": "A",
          "text": "Homologous recombination (HR)",
          "correct": true
        },
        {
          "label": "B",
          "text": "DNA crosslink repair",
          "correct": false
        },
        {
          "label": "C",
          "text": "Non-homologous end joining (NHEJ)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Mismatch repair (MMR)",
          "correct": false
        }
      ],
      "correct_answer": "A. Homologous recombination (HR)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Homologous recombination (HR)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. DNA crosslink repair: Defects in DNA crosslink repair are seen in Fanconi anemia, which presents with bone marrow failure, developmental abnormalities, and increased risk of leukemia, but not the other features seen in this patient.</li><li>\u2022 Option B. DNA crosslink repair:</li><li>\u2022 Option C. Non-homologous end joining (NHEJ): NHEJ is another DNA repair pathway that repairs double-strand breaks. While important for maintaining genomic stability, it's not the primary pathway affected in Bloom syndrome.</li><li>\u2022 Option C. Non-homologous end joining (NHEJ):</li><li>\u2022 Option D. Mismatch repair (MMR): MMR corrects errors that occur during DNA replication. Defects in MMR are seen in Lynch syndrome, which is associated with an increased risk of colorectal and other cancers, but not the characteristic features of Bloom syndrome.</li><li>\u2022 Option D. Mismatch repair (MMR):</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Bloom syndrome is a rare genetic disorder characterized by growth retardation, sun sensitivity, immunodeficiency, and predisposition to various cancers. It is caused by mutations in the BLM gene, which leads to defective homologous recombination and genomic instability.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1e52eb1f",
      "audio": ""
    },
    {
      "text": "A patient with breast cancer is being treated with a drug that stabilizes microtubules, preventing their depolymerization. Which of the following drugs is MOST likely being used?",
      "options": [
        {
          "label": "A",
          "text": "Vincristine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Paclitaxel",
          "correct": true
        },
        {
          "label": "C",
          "text": "Eribulin",
          "correct": false
        },
        {
          "label": "D",
          "text": "5-Fluorouracil",
          "correct": false
        }
      ],
      "correct_answer": "B. Paclitaxel",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Vincristine: Vincristine is a vinca alkaloid that destabilizes microtubules by binding to tubulin and preventing its polymerization. This leads to disruption of the mitotic spindle and cell death.</li><li>\u2022 Option A. Vincristine:</li><li>\u2022 Option C. Eribulin: Eribulin is also a microtubule-destabilizing agent, though its mechanism of action is slightly different from vinca alkaloids. It binds to the plus end of microtubules, preventing their growth and leading to mitotic arrest.</li><li>\u2022 Option C. Eribulin:</li><li>\u2022 Option D. 5-Fluorouracil (5-FU): 5-FU is an antimetabolite that interferes with DNA synthesis. It has no direct effect on microtubules.</li><li>\u2022 Option D. 5-Fluorouracil (5-FU):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The key difference lies in the mechanism of action. Paclitaxel stabilizes microtubules, preventing their normal breakdown, which is essential for cell division. In contrast, vinca alkaloids and eribulin destabilize microtubules, also disrupting cell division but through a different process.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bd1fa20e",
      "audio": ""
    },
    {
      "text": "A 65-year-old man with a 40 pack-year smoking history presents with a persistent cough and hemoptysis. Imaging reveals a central lung mass, and biopsy confirms small cell lung cancer (SCLC). He is started on a chemotherapy regimen including etoposide. Etoposide exerts its anti-cancer effects by targeting a specific phase of the cell cycle. During which phase is etoposide MOST effective?",
      "options": [
        {
          "label": "A",
          "text": "G1 phase",
          "correct": false
        },
        {
          "label": "B",
          "text": "S phase",
          "correct": false
        },
        {
          "label": "C",
          "text": "G2 phase",
          "correct": false
        },
        {
          "label": "D",
          "text": "M phase",
          "correct": true
        }
      ],
      "correct_answer": "D. M phase",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. G1 phase: This is the phase where the cell grows and prepares for DNA replication. Etoposide's mechanism doesn't directly target processes in this phase.</li><li>\u2022 Option A. G1 phase:</li><li>\u2022 Option B. S phase: This is the phase of DNA replication. While DNA damage can occur here, etoposide's primary action is on the M phase.</li><li>\u2022 Option B. S phase:</li><li>\u2022 Option C. G2 phase: This phase involves further cell growth and preparation for mitosis. Again, etoposide's primary target is the M phase.</li><li>\u2022 Option C. G2 phase:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Etoposide is a topoisomerase II inhibitor that is most effective during the M phase of the cell cycle, where it disrupts chromosome segregation and leads to cell death. Understanding the cell cycle specificity of chemotherapy drugs is crucial for optimizing treatment regimens.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f4051472",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman with platinum-resistant ovarian cancer is started on topotecan. You counsel her that this medication works by:",
      "options": [
        {
          "label": "A",
          "text": "Directly blocking DNA synthesis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Preventing cell division by disrupting microtubules",
          "correct": false
        },
        {
          "label": "C",
          "text": "Trapping an enzyme involved in DNA unwinding, leading to DNA breaks",
          "correct": true
        },
        {
          "label": "D",
          "text": "Inserting itself into DNA, causing structural damage",
          "correct": false
        }
      ],
      "correct_answer": "C. Trapping an enzyme involved in DNA unwinding, leading to DNA breaks",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Directly blocking DNA synthesis: While topotecan ultimately disrupts DNA replication, it doesn't directly block DNA synthesis in the same way that antimetabolites do. Antimetabolites, like 5-FU, are structurally similar to DNA building blocks and get incorporated into the DNA strand, thus halting its growth.</li><li>\u2022 Option A. Directly blocking DNA synthesis:</li><li>\u2022 Option B. Preventing cell division by disrupting microtubules: This is the mechanism of action of drugs like taxanes (paclitaxel, docetaxel) and vinca alkaloids (vincristine, vinblastine). They interfere with the formation of the mitotic spindle, which is essential for cell division.</li><li>\u2022 Option B. Preventing cell division by disrupting microtubules:</li><li>\u2022 Option D. Inserting itself into DNA, causing structural damage: This describes the mechanism of action of anthracyclines (doxorubicin, daunorubicin). These drugs intercalate between DNA base pairs, leading to distortion of the DNA structure and interfering with replication and transcription.</li><li>\u2022 Option D. Inserting itself into DNA, causing structural damage:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Topotecan targets topoisomerase I, disrupting DNA replication and causing lethal DNA damage in cancer cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c77cfb5f",
      "audio": ""
    },
    {
      "text": "A 50-year-old woman with breast cancer has completed her primary treatment, which included several cycles of doxorubicin-containing chemotherapy. She is now in remission and attending a follow-up visit with her oncologist. Which of the following long-term complications is the oncologist MOST concerned about?",
      "options": [
        {
          "label": "A",
          "text": "Nausea and vomiting",
          "correct": false
        },
        {
          "label": "B",
          "text": "Alopecia (hair loss)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cardiotoxicity",
          "correct": true
        },
        {
          "label": "D",
          "text": "Myelosuppression (bone marrow suppression)",
          "correct": false
        }
      ],
      "correct_answer": "C. Cardiotoxicity",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Cardiotoxicity</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Nausea and vomiting: While common during active chemotherapy treatment, nausea and vomiting are usually acute side effects and not a significant long-term concern.</li><li>\u2022 Option A. Nausea and vomiting:</li><li>\u2022 Option B. Alopecia (hair loss): Hair loss is another common acute side effect of chemotherapy, but hair usually regrows after treatment is completed.</li><li>\u2022 Option B. Alopecia (hair loss):</li><li>\u2022 Option D. Myelosuppression: Myelosuppression (suppression of bone marrow function, leading to decreased blood cell counts) is a significant side effect during active chemotherapy. However, it typically resolves once treatment is stopped and is not a major long-term concern in the same way as cardiotoxicity.</li><li>\u2022 Option D. Myelosuppression:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anthracyclines, like doxorubicin, can cause delayed cardiotoxicity. Patients who have received these drugs need long-term cardiac follow-up, even years after completing treatment.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a38315cc",
      "audio": ""
    },
    {
      "text": "A 45-year-old man with testicular cancer is scheduled to receive bleomycin- containing chemotherapy regimen. Bleomycin is MOST effective during which phase of the cell cycle?",
      "options": [
        {
          "label": "A",
          "text": "G1 phase",
          "correct": false
        },
        {
          "label": "B",
          "text": "S phase",
          "correct": false
        },
        {
          "label": "C",
          "text": "G2 phase",
          "correct": true
        },
        {
          "label": "D",
          "text": "M phase",
          "correct": false
        }
      ],
      "correct_answer": "C. G2 phase",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) G2 phase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. G1 phase: This is the phase where the cell grows and prepares for DNA replication. Bleomycin's DNA-damaging effects are not specifically targeted to this phase.</li><li>\u2022 Option A. G1 phase:</li><li>\u2022 Option B. S phase: This is the phase of DNA replication. While DNA damage can occur here, bleomycin's peak activity is in the G2 phase.</li><li>\u2022 Option B. S phase:</li><li>\u2022 Option D. M phase: This is the phase of actual cell division (mitosis). While bleomycin-induced DNA damage can also affect mitosis, it's most potent during the G2 phase when the cell is actively preparing for division.</li><li>\u2022 Option D. M phase:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bleomycin is a cell cycle-specific antitumor antibiotic that primarily targets the G2 phase of the cell cycle.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e5dacedf",
      "audio": ""
    },
    {
      "text": "A postmenopausal woman with breast cancer is found to have a tumor that overexpresses aromatase. Which of the following medications is MOST likely to be effective in treating this patient?",
      "options": [
        {
          "label": "A",
          "text": "Tamoxifen",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anastrozole",
          "correct": true
        },
        {
          "label": "C",
          "text": "Fulvestrant",
          "correct": false
        },
        {
          "label": "D",
          "text": "Leuprolide",
          "correct": false
        }
      ],
      "correct_answer": "B. Anastrozole",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Tamoxifen: Tamoxifen is a Selective Estrogen Receptor Modulator (SERM) that acts as an estrogen antagonist in breast tissue but an agonist in other tissues like the bone and uterus. While it can be effective in some cases of hormone-receptor-positive breast cancer, it doesn't directly address the issue of increased estrogen production in tumors that overexpress aromatase.</li><li>\u2022 Option A. Tamoxifen:</li><li>\u2022 Option C. Fulvestrant: Fulvestrant is a Selective Estrogen Receptor Downregulator (SERD) that binds to and degrades estrogen receptors. While effective in hormone-receptor-positive breast cancer, it also doesn't directly target the increased estrogen production in this case.</li><li>\u2022 Option C. Fulvestrant:</li><li>\u2022 Option D. Leuprolide: Leuprolide is a Gonadotropin-Releasing Hormone (GnRH) agonist that suppresses ovarian function, leading to decreased estrogen production. However, it's primarily used in premenopausal women. In postmenopausal women, the ovaries are already inactive, and most estrogen production occurs in peripheral tissues through aromatase.</li><li>\u2022 Option D. Leuprolide:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Aromatase inhibitors are effective in treating hormone-receptor-positive breast cancer in postmenopausal women by reducing estrogen production.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ddfa12e6",
      "audio": ""
    },
    {
      "text": "A 65-year-old man with prostate cancer has been on androgen deprivation therapy (ADT) but recently shows signs of disease progression. His oncologist suspects that his tumor may be utilizing an alternative pathway to maintain androgen signalling. Which enzyme is MOST likely responsible for converting testosterone to a more potent androgen within the prostate, contributing to this resistance?",
      "options": [
        {
          "label": "A",
          "text": "5-alpha reductase (5-AR)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Aromatase",
          "correct": false
        },
        {
          "label": "C",
          "text": "17-alpha hydroxylase (17\u03b11)",
          "correct": false
        },
        {
          "label": "D",
          "text": "CYP17",
          "correct": false
        }
      ],
      "correct_answer": "A. 5-alpha reductase (5-AR)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) 5-alpha reductase (5-AR)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Aromatase: Aromatase converts androgens to estrogens and is relevant in breast cancer, not prostate cancer.</li><li>\u2022 Option B. Aromatase:</li><li>\u2022 Option C. 17-alpha hydroxylase (17\u03b11): This enzyme is involved in the early steps of steroid hormone synthesis in the adrenal glands and gonads. It doesn't directly convert testosterone to DHT.</li><li>\u2022 Option C. 17-alpha hydroxylase (17\u03b11):</li><li>\u2022 Option D. CYP17: CYP17 is another enzyme involved in steroid hormone synthesis, but it doesn't directly convert testosterone to DHT.</li><li>\u2022 Option D. CYP17:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Understanding the role of 5-alpha reductase in androgen metabolism is important for comprehending mechanisms of resistance to hormone therapy in prostate cancer and for selecting appropriate treatment strategies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "53be09f5",
      "audio": ""
    },
    {
      "text": "A patient is about to start a chemotherapy regimen containing high-dose cyclophosphamide (>1500mg/m\u00b2). Which antiemetic regimen is MOST appropriate for preventing CINV in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Dexamethasone alone",
          "correct": false
        },
        {
          "label": "B",
          "text": "5HT3 antagonist alone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dexamethasone + 5HT3 antagonist",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dexamethasone + 5HT3 antagonist + NK1 receptor antagonist",
          "correct": true
        }
      ],
      "correct_answer": "D. Dexamethasone + 5HT3 antagonist + NK1 receptor antagonist",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Dexamethasone + 5HT3 antagonist + NK1 receptor antagonist</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Dexamethasone alone: While dexamethasone has antiemetic properties, it is not sufficient on its own to prevent CINV in high-risk regimens like those involving high-dose cyclophosphamide.</li><li>\u2022 Option A. Dexamethasone alone:</li><li>\u2022 Option B. 5HT3 antagonist alone: 5HT3 antagonists are effective antiemetics, but they are not potent enough to control CINV in high-risk settings when used alone.</li><li>\u2022 Option B. 5HT3 antagonist alone:</li><li>\u2022 Option C. Dexamethasone + 5HT3 antagonist: This combination provides better control than either drug alone, but it may still be inadequate for high-risk chemotherapy. The addition of an NK1 receptor antagonist further enhances antiemetic efficacy in these cases.</li><li>\u2022 Option C. Dexamethasone + 5HT3 antagonist:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 High-risk emetogenic chemotherapy requires a triple-drug antiemetic regimen to effectively prevent CINV.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f539ca2e",
      "audio": ""
    },
    {
      "text": "You are seeing a 60-year-old woman with newly diagnosed breast cancer scheduled to start chemotherapy with a regimen known to have a high risk of causing neutropenia. In which of the following scenarios is the use of G-CSF therapy MOST strongly indicated for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Her current chemotherapy regimen has a 15% risk of causing febrile neutropenia.",
          "correct": false
        },
        {
          "label": "B",
          "text": "She has a history of febrile neutropenia from prior chemotherapy.",
          "correct": true
        },
        {
          "label": "C",
          "text": "She develops a fever and her absolute neutrophil count (ANC) drops to 500/\u00b5L during her current treatment.",
          "correct": false
        },
        {
          "label": "D",
          "text": "She is also scheduled to receive radiation therapy to her chest wall after completing chemotherapy.",
          "correct": false
        }
      ],
      "correct_answer": "B. She has a history of febrile neutropenia from prior chemotherapy.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) She has a history of febrile neutropenia from prior chemotherapy.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Her current chemotherapy regimen has a 15% risk of causing febrile neutropenia. While this is a moderate risk, it's not high enough to warrant primary prophylaxis with G-CSF in the absence of other risk factors.</li><li>\u2022 Option A. Her current chemotherapy regimen has a 15% risk of causing febrile neutropenia.</li><li>\u2022 Option C. She develops a fever and her absolute neutrophil count (ANC) drops to 500/\u00b5L during her current treatment. This scenario indicates the patient has already developed febrile neutropenia. G-CSF would be used for secondary prophylaxis in this case, not primary prophylaxis.</li><li>\u2022 Option C. She develops a fever and her absolute neutrophil count (ANC) drops to 500/\u00b5L during her current treatment.</li><li>\u2022 Option D. She is also scheduled to receive radiation therapy to her chest wall after completing chemotherapy. Radiation therapy to the chest wall can sometimes cause a decrease in blood counts, but it's not a primary indication for G-CSF prophylaxis.</li><li>\u2022 Option D. She is also scheduled to receive radiation therapy to her chest wall after completing chemotherapy.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 A history of febrile neutropenia is a strong indication for G-CSF prophylaxis, even if the current chemotherapy regimen is not considered high-risk. This is because patients who have experienced febrile neutropenia in the past are at a significantly higher risk of developing it again with subsequent chemotherapy. Use if FN risk \u2265 20%, H/o Febrile Neutropenia, Neutropenia prior to starting chemo or active infection while starting chemo.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3d6e2e12",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman with breast cancer is undergoing adjuvant chemotherapy with cyclophosphamide. During her second cycle, she complains of burning sensation while urinating and notices blood in her urine. You suspect a complication due to chemotherapy. Which of the following medications is MOST likely to prevent this complication?",
      "options": [
        {
          "label": "A",
          "text": "Mesna",
          "correct": true
        },
        {
          "label": "B",
          "text": "Dexamethasone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ondansetron",
          "correct": false
        },
        {
          "label": "D",
          "text": "Allopurinol",
          "correct": false
        }
      ],
      "correct_answer": "A. Mesna",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Mesna</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Dexamethasone: A corticosteroid used to manage nausea and vomiting associated with chemotherapy; it has no role in preventing hemorrhagic cystitis.</li><li>\u2022 Option B. Dexamethasone:</li><li>\u2022 Option C. Ondansetron: A 5-HT3 receptor antagonist used to manage nausea and vomiting; it's not effective for preventing hemorrhagic cystitis</li><li>\u2022 Option C. Ondansetron:</li><li>\u2022 Option D. Allopurinol: A medication used to reduce uric acid levels, often in the context of tumor lysis syndrome; it has no role in preventing hemorrhagic cystitis.</li><li>\u2022 Option D. Allopurinol:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Mesna is the standard preventive agent for hemorrhagic cystitis associated with cyclophosphamide. It should be administered concurrently with cyclophosphamide to minimize bladder toxicity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4f3ae253",
      "audio": ""
    },
    {
      "text": "A patient receiving chemotherapy develops a \"glove and stocking\" pattern of numbness and tingling in their hands and feet. Which of the following drugs is MOST likely responsible?",
      "options": [
        {
          "label": "A",
          "text": "Cytarabine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ifosfamide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cisplatin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Gemcitabine",
          "correct": false
        }
      ],
      "correct_answer": "C. Cisplatin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Cisplatin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cytarabine: Cytarabine is primarily associated with cerebellar toxicity and myelosuppression. While it can rarely cause peripheral neuropathy, it is not typically characterized by a glove and stocking distribution.</li><li>\u2022 Option A. Cytarabine:</li><li>\u2022 Option B. Ifosfamide: Ifosfamide can cause hemorrhagic cystitis and neurotoxicity, but the characteristic glove and stocking neuropathy is less common.</li><li>\u2022 Option B. Ifosfamide:</li><li>\u2022 Option D. Gemcitabine: Gemcitabine is associated with myelosuppression, flu-like symptoms, and rash. Peripheral neuropathy is not a typical side effect of this drug.</li><li>\u2022 Option D. Gemcitabine:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Platinum-based chemotherapy agents carry the risk of peripheral neuropathy and ototoxicity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9b02635b",
      "audio": ""
    },
    {
      "text": "A patient receiving CAR T-cell therapy develops fever, hypotension, and tachycardia two days after infusion. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Tumor lysis syndrome",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cytokine release syndrome (CRS)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Graft-versus-host disease (GVHD)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sepsis",
          "correct": false
        }
      ],
      "correct_answer": "B. Cytokine release syndrome (CRS)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Cytokine release syndrome (CRS)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Tumor lysis syndrome: While it can cause fever and electrolyte abnormalities, it's less likely to cause hypotension and tachycardia shortly after T-cell therapy.</li><li>\u2022 Option A. Tumor lysis syndrome:</li><li>\u2022 Option C. GVHD: This occurs in allogeneic stem cell transplantation, not CAR T-cell therapy.</li><li>\u2022 Option C. GVHD:</li><li>\u2022 Option D. Sepsis: Though sepsis can present similarly, the timing and context point more towards CRS in this scenario.</li><li>\u2022 Option D. Sepsis:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 CRS is a serious complication of CAR T-cell therapy characterized by a systemic inflammatory response due to cytokine release.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8e8101b3",
      "audio": ""
    },
    {
      "text": "A 60-year-old man with a history of small cell lung cancer (SCLC) presents with confusion, lethargy, and muscle cramps. Laboratory findings reveal hyponatremia with a serum sodium level of 120 mEq/L, high urine sodium, and high urine osmolality. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Central diabetes insipidus",
          "correct": false
        },
        {
          "label": "B",
          "text": "Nephrogenic diabetes insipidus",
          "correct": false
        },
        {
          "label": "C",
          "text": "Syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Primary hyperaldosteronism",
          "correct": false
        }
      ],
      "correct_answer": "C. Syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Central diabetes insipidus: This condition is caused by deficient production of ADH, leading to excessive water loss and hypernatremia (high serum sodium), not hyponatremia.</li><li>\u2022 Option A. Central diabetes insipidus:</li><li>\u2022 Option B. Nephrogenic diabetes insipidus: In this condition, the kidneys are unable to respond to ADH, also leading to excessive water loss and hypernatremia.</li><li>\u2022 Option B. Nephrogenic diabetes insipidus:</li><li>\u2022 Option D. Primary hyperaldosteronism: This condition is characterized by excessive aldosterone production, leading to sodium retention, hypertension, and hypokalemia. It does not typically cause hyponatremia.</li><li>\u2022 Option D. Primary hyperaldosteronism:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 SIADH is characterized by hyponatremia with inappropriately concentrated urine due to excessive ADH secretion. SCLC is a common cause of SIADH.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dd71ba29",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents with recurrent episodes of flushing, accompanied by diarrhea and abdominal cramping. She has also noticed a rash on her face and neck that worsens during these episodes. On physical examination, you note telangiectasias on her cheeks and a palpable liver mass. Which of the following diagnostic tests is MOST likely to be elevated in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Serum cortisol",
          "correct": false
        },
        {
          "label": "B",
          "text": "24-hour urinary 5-HIAA",
          "correct": true
        },
        {
          "label": "C",
          "text": "Serum calcitonin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Serum gastrin",
          "correct": false
        }
      ],
      "correct_answer": "B. 24-hour urinary 5-HIAA",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 24-hour urinary 5-HIAA</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Serum cortisol: Cortisol is elevated in Cushing's syndrome, which presents with different clinical features (central obesity, muscle weakness, hypertension).</li><li>\u2022 Option A. Serum cortisol:</li><li>\u2022 Option C. Serum calcitonin: Calcitonin is a marker for medullary thyroid carcinoma (MTC), which can also cause flushing but usually presents with a neck mass or thyroid nodules.</li><li>\u2022 Option C. Serum calcitonin:</li><li>\u2022 Option D. Serum gastrin: Gastrin is elevated in gastrinomas (a type of neuroendocrine tumor), which primarily cause peptic ulcers and abdominal pain, not the classic carcinoid syndrome symptoms.</li><li>\u2022 Option D. Serum gastrin:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Carcinoid syndrome is caused by the release of vasoactive substances, mainly serotonin, from carcinoid tumors. 24-hour urinary 5-HIAA is the diagnostic test of choice for carcinoid syndrome.</li><li>\u27a4 Carcinoid syndrome is caused by the release of vasoactive substances, mainly serotonin, from carcinoid tumors.</li><li>\u27a4 24-hour urinary 5-HIAA is the diagnostic test of choice for carcinoid syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4b47e6b9",
      "audio": ""
    },
    {
      "text": "A 50-year-old man presents with persistent bone pain and muscle weakness for several months. He has a history of recurrent fractures. Laboratory findings show hypophosphatemia, normal serum calcium, and decreased 1,25-dihydroxyvitamin D levels. Imaging studies reveal multiple bone lesions. Which of the following is the MOST likely underlying cause of his condition?",
      "options": [
        {
          "label": "A",
          "text": "Primary hyperparathyroidism",
          "correct": false
        },
        {
          "label": "B",
          "text": "Vitamin D deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mesenchymal tumor producing FGF23",
          "correct": true
        },
        {
          "label": "D",
          "text": "Multiple myeloma",
          "correct": false
        }
      ],
      "correct_answer": "C. Mesenchymal tumor producing FGF23",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Primary hyperparathyroidism: This would cause hypercalcemia, not hypophosphatemia.</li><li>\u2022 Option A. Primary hyperparathyroidism:</li><li>\u2022 Option B. Vitamin D deficiency: This would also cause hypophosphatemia, but 1,25-dihydroxyvitamin D levels would be low or inappropriately normal, not decreased.</li><li>\u2022 Option B. Vitamin D deficiency:</li><li>\u2022 Option D. Multiple myeloma: Myeloma can cause bone pain and fractures, but it typically presents with hypercalcemia and renal insufficiency.</li><li>\u2022 Option D. Multiple myeloma:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Oncogenic osteomalacia is a rare paraneoplastic syndrome caused by tumors that secrete FGF23. Recognizing the characteristic clinical and laboratory findings is crucial for prompt diagnosis and treatment. Identifying and removing the underlying tumor can lead to resolution of the osteomalacia.</li><li>\u27a4 Oncogenic osteomalacia is a rare paraneoplastic syndrome caused by tumors that secrete FGF23.</li><li>\u27a4 Recognizing the characteristic clinical and laboratory findings is crucial for prompt diagnosis and treatment.</li><li>\u27a4 Identifying and removing the underlying tumor can lead to resolution of the osteomalacia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "23b267ea",
      "audio": ""
    },
    {
      "text": "A 75-year-old man with a history of atrial fibrillation, diabetes, and peripheral artery disease presents with acute left leg pain, absent pulses, and cold, mottled skin. What is the most appropriate next step?",
      "options": [
        {
          "label": "A",
          "text": "Angiography",
          "correct": false
        },
        {
          "label": "B",
          "text": "Apixaban",
          "correct": false
        },
        {
          "label": "C",
          "text": "Unfractionated heparin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Venous duplex ultrasonography",
          "correct": false
        }
      ],
      "correct_answer": "C. Unfractionated heparin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Angiography : Essential for diagnosis and planning revascularization, but anticoagulation should be started first.</li><li>\u2022 Option A. Angiography</li><li>\u2022 Option B. Apixaban : Oral anticoagulant, not appropriate in the acute setting of ALI.</li><li>\u2022 Option B. Apixaban</li><li>\u2022 Option D. Venous duplex ultrasonography : Not indicated for ALI, which is an arterial problem.</li><li>\u2022 Option D. Venous duplex ultrasonography</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Treat acute limb ischemia with anticoagulation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f9c1e1a5",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman with no medical history presents with frequent, bothersome palpitations that subside with exercise and in the nights. ECG is shown. Echo and baseline lab tests including CBC and TFT are normal. What is the most appropriate management?",
      "options": [
        {
          "label": "A",
          "text": "Amiodarone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Exercise ECG",
          "correct": false
        },
        {
          "label": "C",
          "text": "Propranolol",
          "correct": true
        },
        {
          "label": "D",
          "text": "Reassurance",
          "correct": false
        }
      ],
      "correct_answer": "C. Propranolol",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-172502.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Amiodarone : Antiarrhythmic drug with potential toxicity, not first-line for simple PVCs.</li><li>\u2022 Option A. Amiodarone</li><li>\u2022 Option B. Exercise ECG : Not helpful for diagnosing PVCs.</li><li>\u2022 Option B. Exercise ECG</li><li>\u2022 Option D. Reassurance : Not sufficient for bothersome symptoms.</li><li>\u2022 Option D. Reassurance</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Beta-blockers are the first-line treatment for symptomatic PVCs in patients without structural heart disease.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "06d982a1",
      "audio": ""
    },
    {
      "text": "A 65-year-old man presents with recurrent chest pain and elevated troponin. ECG is shown. remains in pain despite aspirin, clopidogrel, heparin, and nitroglycerin. What is the most appropriate management?",
      "options": [
        {
          "label": "A",
          "text": "Echocardiography",
          "correct": false
        },
        {
          "label": "B",
          "text": "Eplerenone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Oxygen per nasal cannula",
          "correct": false
        },
        {
          "label": "D",
          "text": "Urgent coronary angiography",
          "correct": true
        }
      ],
      "correct_answer": "D. Urgent coronary angiography",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-173300.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Echocardiography : May be helpful, but not the immediate priority.</li><li>\u2022 Option A. Echocardiography</li><li>\u2022 Option B. Eplerenone : Indicated in certain post-MI patients, but not the immediate priority for refractory angina.</li><li>\u2022 Option B. Eplerenone</li><li>\u2022 Option C. Oxygen per nasal cannula : Indicated only if the patient is hypoxic.</li><li>\u2022 Option C. Oxygen per nasal cannula</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Urgent or immediate diagnostic angiography with intent to perform revascularization is indicated in patients with NSTE-ACS who have refractory angina or hemodynamic or electrical instability.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f3f5894f",
      "audio": ""
    },
    {
      "text": "A 68-year-old man with type 2 diabetes, hypertension, hyperlipidemia, and aortofemoral bypass surgery 2 years ago has an HbA1c of 7.1%. His current medications are metformin, atenolol, ramipril, amlodipine, aspirin, rivaroxaban, and atorvastatin. Which medication is most appropriate to add for cardiovascular risk reduction?",
      "options": [
        {
          "label": "A",
          "text": "Clopidogrel",
          "correct": false
        },
        {
          "label": "B",
          "text": "Liraglutide",
          "correct": true
        },
        {
          "label": "C",
          "text": "Niacin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pramlintide",
          "correct": false
        }
      ],
      "correct_answer": "B. Liraglutide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Clopidogrel : Patient is already on rivaroxaban and aspirin. Addition of clopidogrel would not provide any additional benefit and only increase the bleeding risk.</li><li>\u2022 Option A. Clopidogrel</li><li>\u2022 Option C. Niacin : No longer recommended for routine use due to lack of benefit and side effects.</li><li>\u2022 Option C. Niacin</li><li>\u2022 Option D. Pramlintide : Amylin analog used for glycemic control, no proven cardiovascular benefit.</li><li>\u2022 Option D. Pramlintide</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists are associated with reduced rates of adverse cardiovascular events, including stroke, myocardial infarction, and cardiovascular death, compared with placebo.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8acdc0d1",
      "audio": ""
    },
    {
      "text": "A 59-year-old man with type 2 diabetes and a history of stroke is on aspirin, metformin, olmesartan, and rosuvastatin. His LDL-C is 66 mg/dL, HDL-C is 28 mg/dL and HbA1c is 6.8%. What additional medication should be considered for CV risk reduction?",
      "options": [
        {
          "label": "A",
          "text": "Empagliflozin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Ezetimibe",
          "correct": false
        },
        {
          "label": "C",
          "text": "Niacin",
          "correct": false
        },
        {
          "label": "D",
          "text": "No changes in management",
          "correct": false
        }
      ],
      "correct_answer": "A. Empagliflozin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Ezetimibe : Not indicated as LDL cholesterol is already well-controlled.</li><li>\u2022 Option B. Ezetimibe</li><li>\u2022 Option C. Niacin : Can increase HDL but no longer recommended for routine use due to lack of benefit and side effects.</li><li>\u2022 Option C. Niacin</li><li>\u2022 Option D. No changes in management : Inadequate as SGLT2 inhibitors provide additional CV benefit.</li><li>\u2022 Option D. No changes in management</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Consider adding SGLT2 inhibitors to the treatment regimen for patients with type 2 diabetes and established ASCVD to reduce CV risk.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "529899d4",
      "audio": ""
    },
    {
      "text": "A 21-year-old professional gym trainer who is a known type 1 diabetic is about to start a training session. Just before the session, he notices his capillary blood glucose (CBG) to be 280 mg/dL. What should he do?",
      "options": [
        {
          "label": "A",
          "text": "Check ketones",
          "correct": true
        },
        {
          "label": "B",
          "text": "Inject insulin and exercise",
          "correct": false
        },
        {
          "label": "C",
          "text": "Avoid carbohydrates for the day",
          "correct": false
        },
        {
          "label": "D",
          "text": "Recheck CBG the next day",
          "correct": false
        }
      ],
      "correct_answer": "A. Check ketones",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Check ketones</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Inject insulin and exercise: Injecting insulin before exercise could lead to hypoglycemia during the workout, which can be dangerous.</li><li>\u2022 Option B. Inject insulin and exercise:</li><li>\u2022 Option C. Avoid carbohydrates for the day: This could also lead to hypoglycemia as carbohydrates are the primary source of energy for the body.</li><li>\u2022 Option C. Avoid carbohydrates for the day:</li><li>\u2022 Option D. Recheck CBG the next day: Delaying action on elevated blood sugar levels is not recommended and could lead to complications.</li><li>\u2022 Option D. Recheck CBG the next day:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Check for ketones before exercising if blood glucose levels are above 250 mg/dL to prevent the risk of diabetic ketoacidosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "62ea57d7",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman with type 2 diabetes on insulin was recently started on a new drug. After a week, she presents with nausea, vomiting, abdominal pain, near-normal blood glucose, elevated anion gap metabolic acidosis, and elevated plasma ketones. Which of the following medications is the most likely cause?",
      "options": [
        {
          "label": "A",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Canagliflozin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Semaglutide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pioglitazone",
          "correct": false
        }
      ],
      "correct_answer": "B. Canagliflozin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Canagliflozin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Metformin: Metformin can rarely cause lactic acidosis but not associated with euDKA.</li><li>\u2022 Option A. Metformin:</li><li>\u2022 Option C. Semaglutide: Semaglutide (a GLP-1 receptor agonist) is not associated with euDKA.</li><li>\u2022 Option C. Semaglutide:</li><li>\u2022 Option D. Pioglitazone: Pioglitazone (a thiazolidinedione) is not known to cause euDKA.</li><li>\u2022 Option D. Pioglitazone:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Canagliflozin, an SGLT2 inhibitor, can cause euglycemic diabetic ketoacidosis (euDKA).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "47ae46a2",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman with type 2 diabetes mellitus and obesity presents to the clinic. She is currently taking metformin 1000 mg twice daily, but her glycemic control remains suboptimal (HbA1c 8.5%). She is interested in a medication that can help with both weight loss and glucose control. Which of the following medications would be most appropriate for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Liraglutide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dulaglutide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Semaglutide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tirzepatide",
          "correct": true
        }
      ],
      "correct_answer": "D. Tirzepatide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Tirzepatide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Liraglutide, Option B. Dulaglutide and Option C. Semaglutide: While these GLP-1 receptor agonists can promote weight loss and improve glycemic control, tirzepatide has shown superior efficacy in clinical trials compared to these options.</li><li>\u2022 Option A. Liraglutide, Option B. Dulaglutide</li><li>\u2022 Option C. Semaglutide:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tirzepatide, a dual GIP and GLP-1 receptor agonist, is highly effective for both glycemic control and weight loss in type 2 diabetes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a3dd254b",
      "audio": ""
    }
  ]
}